中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
上海药物研究所 [4]
采集方式
OAI收割 [4]
内容类型
期刊论文 [4]
发表日期
2020 [1]
2018 [1]
2017 [1]
2016 [1]
学科主题
筛选
浏览/检索结果:
共4条,第1-4条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
题名升序
题名降序
提交时间升序
提交时间降序
作者升序
作者降序
发表日期升序
发表日期降序
Licochalcone A suppresses the proliferation of sarcoma HT-1080 cells, as a selective R132C mutant IDH1 inhibitor
期刊论文
OAI收割
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 卷号: 30, 期号: 2, 页码: 5
作者:
Hu, Chujiao
;
Zuo, Yu
;
Liu, Jingqiu
;
Xu, Heng
;
Liao, Weike
  |  
收藏
  |  
浏览/下载:26/0
  |  
提交时间:2020/07/01
Licochalcone A
Mutant IDH1
Selective inhibitor
Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 卷号: 152, 页码: 298-306
作者:
Yan, Qi
;
Chen, Yuzhe
;
Tang, Baiyou
;
Xiao, Qiang
;
Qu, Rong
  |  
收藏
  |  
浏览/下载:84/0
  |  
提交时间:2019/01/08
EGFR inhibitors
Pyrimidine derivatives
Mutant selective inhibitors
AZD9291
T790M
Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC
期刊论文
OAI收割
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 140, 页码: 510-527
作者:
Chen, Lingfeng
;
Fu, Weitao
;
Feng, Chen
;
Qu, Rong
;
Tong, Linjiang
  |  
收藏
  |  
浏览/下载:69/0
  |  
提交时间:2019/01/08
Epidermal growth factor receptor
Tyrosine kinase inhibitors
Non-small cell lung cancer
T790M
Mutant-selective
Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors
期刊论文
OAI收割
BIOORGANIC & MEDICINAL CHEMISTRY, 2016, 卷号: 24, 期号: 12, 页码: 2673-2680
作者:
Xiao, Qiang
;
Qu, Rong
;
Gao, Dingding
;
Yan, Qi
;
Tong, Linjiang
  |  
收藏
  |  
浏览/下载:29/0
  |  
提交时间:2019/01/08
5-(Methylthio)pyrimidine derivatives
Mutant selective inhibitors
Epidermal growth factor inhibitor
NSCLC
Structure-based drug design